Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Lenvatinib in TKI-resistant EGFR-mutated NSCLC
NCT05078931Phase 2Active, not recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2021
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Started Oct 2021; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05078931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05078931.